
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Neelam Vashi, MD, FAAD, explains the results of her cross-sectional survey investigating melanoma awareness among different racial and ethnic groups.